Tobacco endgame intervention impacts on health gains and Māori:non-Māori health inequity: a simulation study of the Aotearoa-New Zealand Tobacco Action Plan

Authors:

Driss Ait Ouakrim, Senior Research Fellow, University of Melbourne, driss.aitouakrim@unimelb.edu.au

Tim Wilson, Research Fellow, University of Melbourne, tim.wilson@unimelb.edu.au

Andrew Waa, Lecturer, University of Otago, andrew.waa@otago.ac.nz

Raglan Maddox, Research Fellow, Australian National University, raglan.maddox@anu.edu.au

Hassan Andrabi, Research Assistant, University of Melbourne, hassan.andrabi@unimelb.edu.au

Shiva Raj Mishra, Research Fellow, University of Melbourne, shivaraj.mishra@unimelb.edu.au

Jennifer Summers, Senior Research Fellow, University of Otago, jennifer.summers@otago.ac.nz

Coral Gartner, Associate Professor, University of Queensland, c.gartner@uq.edu.au

Raymond Lovett, Professor, Australian National University, raymond.lovett@anu.edu.au

Richard Edwards, Professor, University of Otago, richard.edwards@otago.ac.nz

Nick Wilson, Professor, University of Otago, nick.wilson@otago.ac.nz

Tony Blakely, Professor, University of Melbourne, <u>ablakely@unimelb.edu.au</u>, Level 3, 207 Bouverie Street, Carlton, VIC, Australia 3053 *

^{*} Corresponding author

Abstract

2 Objective

1

- 3 To estimate the health gains and Māori:non-Māori health inequality reductions of the
- 4 Aotearoa/New Zealand Government's proposed endgame strategy.
- 5 Design
- 6 Simulation modelling: a Markov model to estimate future yearly smoking and vaping
- 7 prevalence (for business-as-usual [BAU] and intervention scenarios) linked to a proportional
- 8 multistate lifetable model with 16 tobacco-related diseases to estimate future morbidity and
- 9 mortality rates, and health adjusted life years (HALYs).
- 10 Setting
- 11 Aotearoa.

- 12 Participants
- Population alive in 2020 (5.08 million) simulated over the rest of their lifespan.
- 15 Interventions
- 1. Denicotinisation of all retail tobacco in 2023, 2. 1 plus media promotion, 3. 95% reduction
- in tobacco retail outlets in 2023, 4. a tobacco free-generation whereby people born in 2006
- and later are never legally able to purchase tobacco, 5. combined package of 2, 3 and 4.
- 19 Main Outcome Measures
- 20 Future smoking prevalence, deaths averted and HALYs by sex and ethnic group. Percent
- 21 reduction in Māori:non-Māori all-cause mortality rate difference in 2040 under interventions
- compared to business as usual (BAU).
- 23 Results
- 24 The combined package of strategies was estimated to reduce adult smoking prevalence from
- 25 31.8% in 2022 to 7.3% in 2025 for Māori, and 11.8% to 2.7% for non-Māori. The 5%

smoking prevalence target was forecast to be achieved in 2026 and 2027 for Māori males and

2 females, respectively. 3 4 The HALY gains for the combined package (compared to BAU) over the population's 5 remaining lifespan was estimated to be 594,000 (95% UI: 443,000 to 738,000; 3% discount 6 rate). The denicotinisation strategy alone achieved 97% of these HALYs, the retail strategy 7 19%, and tobacco-free generation 12%. 8 9 The future per capita HALY gains for the combined package for Māori were estimated to be

- 10 4.75 and 2.14 times higher than for non-Māori females and males, respectively. The absolute
- 11 difference between Māori and non-Māori all-cause mortality for 45+ year olds in 2040 was
- 12 estimated to be 23.4% (19.1% to 27.6%) less for females under the combined package
- 13 compared to BAU, and 9.5% (7.5% to 11.3%) less for males.

14 Conclusion

- 15 A tobacco endgame strategy, especially denicotinisation, could dramatically reduce health
- 16 inequities.

1

Funding 17

19

18 New Zealand Ministry of Health.

Statements

2 Ethics

1

9

21

- 3 Ethics approval was not required for this study, as only secondary data sources were used.
- 4 Transparency statement
- 5 The lead author (DAO) and senior author (TB) jointly guarantee that the manuscript is an
- 6 honest, accurate, and transparent account of the study being reported. In addition, the authors
- 7 indicate that no important aspects of the study have been omitted, and that any discrepancies
- 8 from the study as originally planned (and, if relevant, registered) have been explained.
- 10 This research is funded by the NZ Ministry of Health and has the potential to dramatically
- affect the health of people in Aotearoa, especially Māori. Accordingly, additional
- transparency steps have taken place. These include: an extensive dialogue with the Ministry
- of Health staff and the NZ Associate Minister of Health on findings (they have not
- contributed to write-up), earlier results from this modelling have been used as a regulatory
- 15 impact statement accompanying a policy proposal to Cabinet, and early dissemination with
- 16 key Māori stakeholder groups in Aotearoa and international tobacco control researchers has
- 17 been undertaken.

18 Contributorship

- 19 Our team brings Māori lived experience (AW), Indigenous lived experience (RM, RL), and
- 20 experience in research on tobacco inequalities (AW, RM, CG, RL, RE, NW, TB).
- 22 DAO, JS, NW and TB led the conceptualisation of the computer simulation modelling with
- data and other input specified by TW, HA and SRM. DAO and TW led the analyses and
- 24 production of outputs, tables and figures. All authors contributed to data interpretation. AW,
- 25 RM and RL initiated the drafting of the Introduction and Discussion, TB led the Methods and
- 26 Results, and DAO led the Appendix. All authors revised the draft manuscript critically for
- 27 important intellectual content.

Role of the funding source

- 2 The views expressed in this report are solely the responsibility of the authors and they do not
- 3 necessarily reflect the views, decisions, or policies of the institutions with which they are
- 4 affiliated, of the NZ Ministry of Health or Government.
- 6 Specifically, the NZ Ministry of Health:
- 7 funded the initial analyses
- 8 did not contribute to drafting this paper
- 9 did contribute to conceptualization of the interventions, as they are integral to the NZ
- 10 Action Plan
- did provide NZ Health Survey data to parametrise the smoking-vaping life history
- Markov model.

13 Declarations of Interest

14 NA

1

5

- 15 Acknowledgements
- 16 NA

17

25

18 Exclusive Licence statement

- 19 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the
- Work (as defined in the author licence), an exclusive licence and/or a non-exclusive licence
- 21 for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a
- 22 CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal
- 23 Government officers or employees acting as part of their official duties; on a worldwide,
- perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees.
- The Submitting Author accepts and understands that any supply made under these terms is
- 27 made by BMJ to the Submitting Author unless you are acting as an employee on behalf of
- 28 your employer or a postgraduate student of an affiliated institution which is paying any
- 29 applicable article publishing charge ("APC") for Open Access articles. Where the Submitting
- 30 Author wishes to make the Work available on an Open Access basis (and intends to pay the
- 31 relevant APC), the terms of reuse of such Open Access shall be governed by a Creative
- 32 Commons licence details of these licences and which licence will apply to this Work are set
- out in our licence referred to above.

Summary boxes

1

What is already known on this topic

- Modelling of health gains and health inequality reductions for some tobacco endgame
- 4 strategies has been undertaken internationally, and specifically in Aotearoa (tobacco
- free generation policy, substantial reductions in the number of tobacco outlets
- 6 including, a sinking lid that gradually phased out all tobacco supply between 2011 to
- 7 2025, restricting tobacco sales to pharmacies only with brief cessation advice
- 8 provided to consumers). All modelling suggested that these interventions improved
- 9 equity, of varying magnitude, in either smoking prevalence or health gain for Māori
- 10 compared to non-Māori.
- Endgame modelling of denicotinisation has not been undertaken, alone or in
- combination with other interventions. The interplay of tobacco smoking and vaping
- has not been explicitly included in endgame modelling. The package of endgame
- 14 strategies in the Aotearoa-New Zealand Government's Smokefree Action Plan (Dec
- 15 2021) have not been modelled.

What this study adds

- The Government's package (denicotinisation of retail tobacco, 95% reduction in the
- number of tobacco retail outlets; and a tobacco-free generation) if implemented in
- 19 2023 is forecast to achieve less than 5% smoking prevalence by 2025 for non-Māori,
- and by 2027 for Māori.

- Denicotinisation is estimated to achieve the majority of the health gains.
- A 95% retail outlet reduction and a tobacco-free generation, on their own, are unlikely
- to achieve a 5% smoking prevalence for any sex by ethnic groups until at least 2040.
- The combined package, compared to BAU, is estimated to reduce the Maori:non-
- 25 Māori gap in 45+ year old all-cause mortality in 2040 by 22.9% (95% uncertainty
- 26 interval 19.9% to 26.2%) for females and 9.6% (8.4% to 11.0%) males.

Introduction

1

2 Despite unequivocal evidence about the harm caused by commercial tobacco, it continues to be a leading cause of avoidable morbidity and mortality. Smoking prevalence in high income 3 countries with colonial histories has steadily decreased over recent decades, but prevalence 4 among Indigenous peoples is often substantially higher² than in the general population and is 5 6 a significant contributor to health inequities.³ 7 8 Indigenous people's experiences of colonisation include imposition of alien societal 9 institutions, appropriation of economic resources and exposure to racism. Referred to as 'basic causes' 45, these affect access to social determinants of health (e.g., income, housing) 10 11 and, via health behaviours such as smoking rates, ultimately leading to racialised health 12 inequities. In many instances this has been compounded by the use of tobacco as a trade commodity. Since the late 19th century, tobacco companies have actively exploited and 13 promote commercial tobacco to Indigenous peoples.²⁶⁷ 14 15 16 In 2020-21, 22.3% of Māori (the Indigenous peoples of Aotearoa/New Zealand [A/NZ]) 15 17 years and older smoked at least daily. This was 2.7 times the prevalence among European/Others (8.3%; NZ Health Survey).8 18 19 20 Similar to other high-income countries, A/NZ's tobacco control programme includes: 21 restricting the promotion of tobacco products, providing cessation support, implementing 22 mass media campaigns, regular increases in tobacco excise tax, and smokefree area policies.⁹ 23 Many of these measures have some reliance on individual capacity and access to resources 24 needed to carry out desired behaviours such as quitting cigarettes. These resources are 25 inequitably distributed across the A/NZ population, likely explaining a failure of A/NZs 26 tobacco control programme to address smoking disparities. Concern about the slow progress 27 in reducing smoking prevalence among Māori, led Māori political and tobacco control 28 leaders to propose a tobacco endgame in the mid-2000s. Instead of focusing on people who 29 smoke, they argued that the tobacco industry and the products they sell should be targeted. In 30 2011 the A/NZ Government committed to achieving a Smokefree country by 2025¹⁰ 31 (commonly interpreted as less than 5% smoking prevalence among both Māori and non-

1 Māori). Achieving this goal required a radical departure from business as usual (BAU) approaches ¹¹, but actual tobacco control policy remained relatively unchanged. The 2010s 2 3 coincided with the proliferation of alternative nicotine delivery devices and, in particular, 4 electronic cigarettes, and introduced a discourse about 'harm minimisation' to the tobacco endgame debate. ¹² A more holistic notion of 'harm' expressed among many Māori includes 5 6 addiction as well as health harm, meaning that achieving an end to both nicotine addiction as 7 well as tobacco smoking is the desired endgame. 8 9 The A/NZ Government launched an Action Plan in late 2021 to achieve the country's endgame objective. 13 This plan focused on smoked tobacco and sought to bring about rapid 10 11 and profound reductions in smoking prevalence, and to do so equitably such that all 12 population groups (in particular Māori) achieve minimal smoking prevalence by 2025. Three 13 key ('endgame') strategies were identified in the Action Plan to achieve this goal: 14 denicotinising retail tobacco to non-addictive levels (e.g., ≤0.4mg nicotine/cigarette)¹⁴ 15 markedly reducing retail access to tobacco, and creating a 'Tobacco-free Generation'. The 16 latter would be achieved by progressively raising the legal age at which tobacco can be sold 17 to young people. These measures do not directly address basic causes or social determinants 18 of smoking related inequities. However, they substantively circumvent the role of agency 19 (e.g., individual access to necessary social or economic resources) in being able to quit 20 smoking or resisting initiation. As such, they have strong potential to bring equitable change in smoking behaviour. 15 A challenge of these types of measures is that they would act against 21 Indigenous aspirations of empowerment and self-determination ¹⁶ if they were enacted by a 22 23 predominantly non-Indigenous government 'on' Māori. The Action Plan has sought to 24 address this issue by seeking Māori engagement throughout the planning and policy 25 development stages, including establishing a Māori Governance group. 26 27 Internationally, there is growing interest in tobacco endgame goals and strategies, with an 28 increasing number of countries adopting endgame goals and a range of bold endgame 29 interventions proposed. Scotland, for example, has included a strong focus on equity within their endgame goals and strategies, ¹⁷ but, other than in A/NZ, a focus on Indigenous health 30 31 inequities has not been a key objective of endgame strategies. To date, the implementation of 32 endgame interventions has been minimal and, consequently, the evidence base of their

potential effects is weak. 18 For example, none of the endgame interventions included in the

A/NZ Action Plan have been implemented at country-level, with the possible exception of

substantial reductions in retail supply in Hungary.

- 5 This paper aimed to estimate the future tobacco smoking prevalence, mortality and health
- 6 adjusted life year (HALY) impacts (including changes in Māori/non-Māori inequalities) of
- 7 tobacco endgame strategies outlined in the A/NZ Government's proposed Action Plan.
- 8 Specific research questions were:

2

3

4

12

23

29

- 9 1. Which endgame strategies have the potential to reduce smoking prevalence to less than 5% for all sex and ethnic groups by 2025?
- 2. Which endgame strategies maximally reduce Māori/non-Māori health inequalities?
- We used simulation modelling to calculate these estimates, using a hierarchy of data inputs
- 14 ranging from trial evidence (e.g., for very low nicotine cigarettes) to observational evidence
- 15 (e.g., smokers response to what they would do in the face of policies proposed) to expert
- 16 knowledge elicitation when required. Forecasting the future is uncertain. Accordingly, all
- input parameters have uncertainty related to them that the reader can inspect, all outputs
- 18 incorporate uncertainty due to the propagated input parameter uncertainty in Monte Carlo
- simulation, and we tease apart which input parameter uncertainty drives most of the output
- 20 uncertainty. A key principle of this study is that even if as a research community we do not
- 21 have ideal data, decision makers and society need the best estimates we can produce, with
- 22 appropriate depiction and caveats about inevitable uncertainty.

Methods

- We used an existing tobacco simulation model¹⁹⁻²¹ (rated as best of 25 tobacco models
- 25 globally²²), and expanded its capabilities to create a new model called Scalable Health
- 26 Intervention Evaluation (SHINE) tobacco, which includes a Markov smoking and vaping life
- 27 history model and functionality for outputting packages of interventions and mortality rates
- 28 by time.

Smoking and vaping life history model 1 2 We developed a Markov model to simulate population smoking and vaping behaviours, based 3 on seven states (Supplementary Figure S1, Table S1): never smoker (NS), current smoker 4 (CS), never smoker current vaper (NSCV), dual user (DU), former smoker current vaper 5 (FSCV), former smoker and/or former vaper (FSFV), never smoker former vaper (NSFV). 6 Movement between states are determined by transition probabilities, which reflect BAU and 7 the potential effects of interventions (below). Initiation of smoking (transition from NS to CS 8 or DU) and vaping (transition from NS to NSCV) was assumed to occur at age 20 years. 9 From the age of 20 onwards, any quitting of smoking was assumed permanent, parameterised 10 as a 'net' cessation rate from CS and DU to either FSCV or FSFV. For proportions of the 11 cohort in the FSCV state, there was an annual net transition probability to FSFV, but no 12 return flow from FSFV to FSCV. The FSFV, FSCV and NSFV states were additionally 13 modelled as 20-year tunnel states that the cohort progressed through each year, allowing the 14 model to identify how many years each cohort was from quitting so as to incorporate 15 decaying impacts of smoking on disease incidence by time since quitting (see below). 16 17 To specify the transition probabilities under BAU, we first estimated future daily smoking 18 (and vaping) rates by extrapolating trends in the 2013-14 to 2019-20 New Zealand Health 19 Survey (NZHS) data, using a two-step regression approach: 1) a best fit regression model to 20 historic data; and 2) a regression model on the former predictions by sex, age and ethnicity to 21 generate annual net cessation rates by cohort as they age, and annual trends in initiation. 22 23 We then calculated annual transition probabilities to achieve these projections, starting with 24 transition probabilities between the seven states from the United Kingdom as reported by 25 Doan et al.²³ (Supplementary Table S2), modifying them as required (with mathematical 26 optimisation using Excel Solver) to meet the above projections. We performed this operation 27 by sex and ethnicity for three age cohorts (20-24, 40-44, and 60-64), and interpolated other 28 age cohorts.

Proportional multistate lifetable model

1

17

- 2 A proportional multistate life table (PMSLT) was used to estimate health impacts of smoking
- and vaping under BAU and intervention scenarios (key input parameters in Table 1). A
- 4 detailed description of the model has been provided elsewhere. 24 Briefly, the PMSLT is
- 5 composed of a main cohort lifetable, which simulates the entire A/NZ population alive in
- 6 2020 until death using projected all-cause mortality and morbidity rates by sex, age, and
- 7 ethnicity (Ma□ori, non-Ma□ori). Thus, for the youngest people we are estimating HALYs as
- 8 far out as calendar years 2131; however, we focus on the next 20 years in much of the results.
- 9 In parallel, proportions of the cohort also reside in 16 subsidiary tobacco-related disease
- 10 lifetables according to prevalence at baseline (i.e., start of model), and in future years based
- on BAU disease-specific incidence, case fatality and remission rates. Within each disease
- lifetable, morbidity estimates (i.e. disability rates from the NZ Burden of Disease Study²⁵) are
- 13 attached to prevalent cases. The tobacco-related diseases included in the model are: coronary
- heart disease, stroke, chronic obstructive pulmonary disease (COPD), lower respiratory tract
- infection (LRTI), and twelve cancers (lung, oesophageal, stomach, liver, head and neck,
- pancreas, cervical, bladder, kidney, endometrial, melanoma, and thyroid).
- 18 Within each disease lifetable, an intervention is run in parallel to BAU with different disease
- incidence rates given changes in smoking and vaping life histories (see next section). Each
- 20 disease lifetable estimates the difference between intervention and BAU in disease mortality
- and morbidity rates that are then added to matching entities in the main lifetable.
- 22 Connecting the smoking-vaping life history model to the PMSLT using
- 23 population impact fractions
- 24 For each sex by age by ethnic group, and each annual time step into the future, a population
- 25 impact fraction (PIF) is calculated for each tobacco-related disease. The generic formula²⁶ is:

$$PIF_{idt} = \frac{\sum_{j=1}^{n} P_{ijt} RR_{idj} - \sum_{j=1}^{n} P'_{jt} RR_{idj}}{\sum_{j=1}^{n} P_{ijt} RR_{idj}}$$

- 27 where: *i* subscripts each sex by age by ethnic group, d subscripts each disease, t subscripts
- each time step or yearly cycle, *j* subscripts *n* states in the smoking-vaping life history model,

1 RR is the incidence rate ratio for disease d and smoking-vaping state j, and possible varying 2 by demographics (e.g., by sex and age, but not by ethnic group (note the RR does not vary by 3 time step t), and P(P) is the proportion of the demographic cohort (i) in each of j states in 4 each time step t. These PIFs are the percentage change in incidence rates for each smoking 5 related disease inputted to the PMSLT. 6 7 The source and values of the tobacco-related disease incidence rates and rate ratios are given 8 in Appendices A-B and Supplementary Tables S3-S19. Harm from vaping was modelled as 5% to 20% of tobacco harm following Mendez and Warner²⁷ (Beta distribution with median 9 11% and 95% uncertainty interval [UI] of 5% to 20%). 10 11 Interventions To parameterise the intervention scenarios we adapted initial estimates by Wilson et al,²⁸ 12 13 which derived their potential effects based on A/NZ-specific literature (including a 14 randomised trial of denicotinised cigarettes) and international literature; adaptation for this 15 paper included incorporating additional research and expert judgements by the authors. The 16 intervention specifications are shown in Table 2; below we give key parameters (and there 17 uncertainty intervals that are sampled from in Monte Carlo simulation). Briefly: 18 Denicotinisation: initiation was estimated to reduce to 10% (95% UI 2.6% to 19 21.5%) of that in BAU by five years after implementation; cessation transition 20 probabilities were increased so that over five years the smoking prevalence in CS 21 and DU states was 15.2% (95% UI 3.7% to 32.9%) of that in BAU, and from the 22 sixth-year onward cessation transition probabilities were doubled. 23 Denicotinisation plus mass media: as above, plus an extra increase in cessation 24 rates in the first five years of 2.1% (equivalent to twice the impact of past Quitline 25 media campaigns in A/NZ on net cessation rates). 26 Retail outlet reduction: we used the average of two inputs: a) previous modelling by ourselves ²⁹ of increasing travel time, converted to cost and then through price 27 elasticities that estimates a 15.8% reduction in smoking prevalence in the year of 28 29 implementation, b) 23.0% of respondents (smokers) to the NZ International 30 Tobacco Collaboration study saying they would quit if outlets reduced by 95%.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19 20

21

22

23

24 25

26

27

BAU.

We used the average of these two (19.4%; 95% UI 12.9% to 26.9%) as the one-off increase in net cessation in the year of the policy implementation. The same magnitude reduction in initiation was included in the year of implementation and all subsequent years. Tobacco-free generation: in theory, initiation will reduce to zero. In practice, social supply is likely. The exact reduction in initiation is uncertain, so we specified that future initiation rates will be 10% of BAU with wide uncertainty (95% UI: 2.6% to 21.5%), achieved 10 years after the policy is introduced. Analyses and parameter uncertainty We produced the following outputs. First, deaths averted by time period. Second, healthadjusted life years (HALYs; 3% annual discount rate) gained from each intervention, both the total number and age-standardised (using Māori population 2020) per 1000 people. Third, we calculated the age-standardised all-cause mortality rate differences between Māori and non-Māori (by sex) for 45+ year old (by age in the future), under BAU and each intervention, and presented the percentage difference in the rate difference for each intervention compared to The BAU and each intervention scenario were simulated 2000 times using Monte Carlo simulation, drawing from the probability density functions specified in Tables 1 and 2. To help understand the uncertainty in our modelling, we used univariate sensitivity analyses to depict which input parameter uncertainty generates the most uncertainty in lifetime HALY gains for all sex and ethnic groups combined for the combination endgame policy package compared to BAU. The result is presented as a 'Tornado Plot' showing the changes in model outputs for selecting the 2.5th and 97.5th percentile of each input parameter in turn (holding all other inputs at their expected value).

Results

1

2 Achieving < 5% prevalence</p>

- 3 The modelled combined package achieves a profound and rapid reduction in smoking
- 4 prevalence (Figure 1 and Supplementary Table S23). In 2022, the year before policy
- 5 implementation, Maori age 20+ smoking prevalence is 31.8%, falling to 28.7% (95% UI:
- 6 25.5% to 30.4%) under BAU by 2025 (the year targeted to have smoking prevalence less than
- 7 5% by the A/NZ Parliament). Under the combined package Māori smoking prevalence
- 8 decreases to 7.3% (3.9% to 9.2%) in 2025 (females: 8.2%, 4.3% to 10.5%; males: 6.3%,
- 9 3.4% to 7.9%). For non-Māori, the smoking prevalence is 11.8% in 2022, falling to 10.8%
- 10 (95% UI: 9.6% to 11.2%) in 2025 under BAU and decreasing to 2.7% (1.4% to 3.5%) under
- 11 the combined package (females: 2.5%, 1.3% to 3.3%; males: 2.9%, 1.5% to 3.8%). The
- combined package achieves the under 5% smoking prevalence target in 2026 and 2027 for
- 13 Māori males and females, respectively.
- 15 Denicotinisation causes the majority of forecasted decreases in smoking. Retail outlet
- reduction has a strong impact in its year of implementation (due to a large cessation impact),
- but it then tracks largely as in BAU (as no ongoing increases in cessation are assumed, and
- 18 reductions in initiation take years to accrue). Neither the retail reduction nor the tobacco-free
- 19 generation strategies achieve less than 5% smoking prevalence by 2025 for any sex by ethnic
- 20 group.

14

21 Deaths averted

- 22 Under the combined policy package, deaths up to 2040 were 8,150 (95% UI: 6,450 to 9,890)
- less than under BAU, with 27% to 30% of these averted deaths among each of female Māori,
- 24 female non-Māori and male non-Māori (Table 3).

25 HALYs gained

- 26 For the combined intervention compared to BAU, by sex and ethnic group, 28% to 30% of all
- 27 HALYs gained by the combined package were among female Māori, female non-Māori and
- male non-Māori, with a lesser 14% among male Māori. For sexes and ethnic groups
- 29 combined, and for the remainder of the lifespan of the population alive in 2020, there was an

- 1 estimated 594,000 HALYs gained (95% UI: 443,000 to 738,000: bottom right of Table 4).
- 2 The majority (90%) of these HALYs gained were after 2040.
- 3 The denicotinisation strategy alone achieves 97% of the HALYs of the combined package,
- 4 retail outlet reduction alone 19% and the tobacco-free generation alone 12%. For the tobacco-
- 5 free generation, the vast majority (98%) of HALYs gained over the lifespan of the population
- 6 occurred after 2040. Supplementary Figure S3 provides a comparison in terms of health gains
- 7 from the endgames strategies evaluated in this paper with other large scale public health
- 8 policies (modelled or already in place) in A/NZ.

Inequality impacts

9

16

26

27

- 10 Figure 2 shows the ratio of age-standardised per capita HALYs gains for Māori compared to
- 11 non-Māori. For the combined package, Māori females gained 4.75 times as many HALYs per
- capita as non-Māori females, and Māori males gained 2.15 times as many as non-Māori
- males. The Māori:non-Māori ratio of per capita HALY gains was similar for other
- interventions, except it was higher for the tobacco-free generation (noting, though, that the
- absolute gains were less for this strategy see Supplementary Table S24).
- Māori 45+ years mortality rates in 2040 are 11.6% and 5.2% lower under the combined
- package than under BAU, for females and males respective. For non-Māori, these reductions
- are less at 2.8% and 2.3%, for females and males respectively. The impact of the combined
- 20 endgame strategies on the Māori compared to non-Māori 'gap' (absolute difference) in
- 21 mortality rates by 2040 is shown in Figure 3. The rate difference is 23.4% (95% UI: 19.1% to
- 22 27.6%) less for females for the combined package compared to BAU, and 9.5% (95% UI:
- 23 7.5% to 11.3%) less for males. The denicotinisation policy alone achieves most of this
- 24 mortality rate inequality reduction, and the retail reduction strategy about a quarter of that for
- 25 the combination strategy.

Sensitivity analyses

- 28 Figure 4 shows a Tornado plot of how much variation in lifetime HALYs gained (combined
- 29 endgame policy; 3% discount rate) resulted from univariate sensitivity analyses about the key
- 30 intervention parameters. Uncertainty about the cessation rate due to denicotinisation was

- 1 clearly the major source of overall uncertainty in HALYs gained: the 97.5th percentile value
- 2 of increased cessation leading to 32.9% of BAU smoking prevalence (or conversely a 67.1%
- 3 reduction in smoking prevalence due to increased cessation) led to 545,000 HALYs gained
- 4 (end of blue bar in Figure 4) compared to 653,000 HALYs gained (end of red bar) for the
- 5 2.5th percentile value of 3.7% of BAU smoking prevalence due to cessation (or conversely a
- 6 large 96.3% reduction in smoking prevalence due to increased cessation). Uncertainty about
- 7 other key input parameters generate considerably less uncertainty in the HALYs gained.

In Aotearoa-New Zealand (A/NZ), a post-colonial country with a high smoking rates among

the Indigenous Māori, we found that tobacco endgame strategies outlined in the December 2021 A/NZ Smokefree Plan ¹³, in particular denicotinisation of commercial tobacco, could

Discussion

1

2

3

4 5

6

7

8

9

10

11

12 13

14

15

16

17

18

19

20

21 22

23

24

25

26

27

28

29 30

31 32 have a profound positive impact on the health of Māori and notably reducing health inequity between Māori and non-Māori. For example, by 2040, a combined package including denicotinisation plus media, 95% reduction in retail outlets and a tobacco-free generation would – we estimate – reduce the gap in the mortality rate of people aged 45 years and older by 23.4% (95% UI 19.1% to 27.6%) for females and 9.5% (7.5% to 11.3%) for males, compared to ongoing BAU. It is unlikely that any other feasible health intervention would reduce ethnic inequalities in mortality by as much. Our forecasts suggest mandating denicotinisation would have an immediate, marked and enduring impact on smoking prevalence in A/NZ. Importantly the impacts of this measure would make a significant contribution towards eliminating smoking prevalence inequities between Māori and non-Māori populations. Reducing retail access would have a lesser impact on overall prevalence and inequities and introducing a tobacco-free generation alone would take many years to take full effect with impact on smoking prevalence and then health gains. Nevertheless, the impacts of both of these measures are on par with tobacco tax increases, 30 and greater than interventions such as mass media and quit programmes alone. 31 The profound impact of tobacco endgame strategies on ethnic health inequalities in A/NZ shown in the model is due to higher smoking rates among Māori (especially females), but also because the smoking-related disease rates are higher among Māori (for both tobacco and non-tobacco-related reasons). Such patterning by indigeneity, ethnicity and socioeconomic position occurs in many other countries, suggesting tobacco endgame strategies will notably reduce health inequities in other countries – as well as improving the health of all citizen groups. Tackling tobacco is not only a health issue, it has also a social and economic priority for Indigenous peoples.³² Whilst not presented in this paper, modelling we conducted for the A/NZ Government to underpin the Action Plan estimated income gains of US\$ 1.42 billion 17

1

2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

by 2040 (3% discount rate) due to the income gains occurring among those not dying prematurely or developing chronic disease, a fillip to the A/NZ productivity and GPD overall but also a pro-equity economic boost for Māori communities. Colonisation is an underlying driver of ethnic inequalities in smoking behaviour. Māori engagement and leadership throughout the process of developing and subsequent implementation of A/NZs Action Plan has been essential to ensure the Plan itself is not a further expression of coloniality. Legislation for the actual implementation of the Plan is expected to happen during 2022 with different measures coming into force over the next few years. Other than a temporary ban on tobacco sales in Bhutan, no country has implemented any of the endgame interventions proposed in the A/NZ Action Plan. This lack of evidence about the real-world impacts of endgame strategies means that modelling studies' assumptions about likely impact are based on theory, logic, expert views and simulation studies. It is therefore imperative that where endgame strategies are implemented, they are robustly evaluated to provide evidence to better inform decision-making and improve modelled estimates such as in this current study. Second, such evaluations should include a thorough investigation of equity issues, including where applicable, the exploration of intended and unintended impacts on Indigenous peoples. Thirdly, the striking equity impacts of endgame interventions estimated in this study underline that future tobacco control modelling studies should explore impacts on inequities in smoking prevalence and smoking-related disease. Strengths and limitations Given data limitations, expert judgement and estimates from scenario studies were used in specifying the impacts of endgame policies. We specified substantial uncertainty about most of these inputs (Table 2), then used Monte Carlo simulations to generate uncertainty about the outputs of HALYs gained and mortality impacts. The uncertainty intervals of the HALYs, for example, are non-overlapping between the denicotinisation and retail interventions, and with BAU, suggesting a strong degree of confidence in the likely magnitude of health gains and inequality impacts. Univariate sensitivity analyses for the combined interventions policy package (Figure 4) clearly show that uncertainty about how much cessation will reduce with

1

2

3

4

5

6

7

8

9

10

11

12

1314

15

16

17

18 19

20

21

22

23

2425

26

27

28

29

30

31

a denicotinisation policy is the key uncertainty in our modelling. That said, even for this cessation impact varying widely from a 67.1% to 96.3% reduction in prevalence, the lifetime HALY gains were always substantial (range 545,000 to 653,000). We used 2013-14 to 2019-20 health survey data to parametrise our smoking-vaping life history model. Since then, 2020-21 data has found a marked drop in smoking prevalence in all socio-demographic groups. If this drop is not just a statistical anomaly, then we may have over-estimated smoking rates in the base year and BAU in the future, therefore overestimating HALY gains and mortality rate reductions arising from endgame strategies. Second, we assumed all uptake occurred at age 20, and report smoking prevalence for 20+ year olds; had we used 15+ year olds as our denominator, the smoking prevalence results reported would have been lower. A/NZ has a fairly liberal access to alternative nicotine products, such as vaping. This meant that in our modelling, some people quitting tobacco took up vaping for a while at least (Supplementary Table S24). The generalisability of our study to other countries will depend partly on their regulatory environment for vaping. Homegrown tobacco for personal recreational use, and illicit supply, may provide some alternative tobacco source in A/NZ with denicotinisation or substantial reduction in retail access. However, homegrown tobacco is uncommon in A/NZ due to a non-ideal physical environment in most of A/NZ for growing, and tight border security in an island nation with no land borders reduces the potential of an illicit market. We have highlighted the importance of Māori and Indigenous engagement in the development and implementation of A/NZ's Action Plan. The Plan also draws attention to the need for research and evaluation to provide an accountability mechanism to Māori. In this paper we attempted to uphold Indigenous Data Sovereignty principles, including Māori and other First peoples contributors (AW, RM and RL), providing data analysed against Indigenous population norms and including Indigenous interpretations. But more should be done in the future to engage Maori governance of research alongside the implementation of

- the Action Plan, facilitating Māori researchers undertaking that research where practicable,
- 2 and prioritizing dissemination of findings to Māori communities first.

4 Conclusion

3

8

- 5 Many countries have Indigenous, ethnic and socio-economic inequalities in tobacco use.
- 6 This modelling study suggests that tobacco endgame strategies could have major impacts
- both on overall health status, and on reducing inequalities in health.

References

- 2 1. WHO. Tobacco: Key Facts 2021 [Available from: https://www.who.int/news-room/fact-sheets/detail/tobacco accessed 17 Jan 2022.
- 4 2. Maddox R, Waa A, Lee K, et al. Commercial tobacco and indigenous peoples: a stock take
 5 on Framework Convention on Tobacco Control progress. *Tobacco Control* 6 2019;28(5):574-81.
- 3. Blakely T, Disney G, Valeri L, et al. Socioeconomic and Tobacco Mediation of Ethnic
 Inequalities in Mortality over Time: Repeated Census-mortality Cohort Studies, 1981
 to 2011. Epidemiol 2018;29(4):506-16. doi: 10.1097/EDE.0000000000000842
 [published Online First: 2018/04/12]
- 4. Williams DR, Mohammed SA. Racism and health I: Pathways and scientific evidence.
 American behavioral scientist 2013;57(8):1152-73.
- 5. Waa A, Robson B, Gifford H, et al. Foundation for a Smoke-Free World and healthy
 Indigenous futures: an oxymoron? *Tobacco Control* 2019;29:237-40. doi:
 http://dx.doi.org/10.1136/tobaccocontrol-2018-054792
- 6. Maddox R, Bovill M, Waa A, et al. Reflections on Indigenous commercial tobacco
 control: 'The dolphins will always take us home': BMJ Publishing Group Ltd, 2022.
- 7. Waa A, Maddox R, Henderson PN. Big tobacco using Trojan horse tactics to exploit Indigenous peoples. *Tobacco Control* 2020;29(e1):e132-e33.
- 8. Ministry of Health. 2021. Annual Data Explorer 2020/21: New Zealand Health Survey [Tobacco Use]. URL: https://minhealthnz.shinyapps.io/nz-health-survey-2020-21- annual-data-explorer/.
- 9. New Zealand Ministy of Health. Report back on New Zealand's Tobacco Control
 Programme, 2016.
- 10. New Zealand Parliament. Government Response to the Report of the Māori Affairs
 Committee on its Inquiry into the tobacco industry in Aotearoa and the consequences
 of tobacco use for Māori (Final Response). Wellington: New Zealand Parliament,
 2011.
- 11. van der Deen F, Ikeda T, Cobiac L, et al. Projecting future smoking prevalence to 2025
 and beyond in New Zealand using smoking prevalence data from the 2013 Census.
 NZMJ 2014;127(1406):1-9.
- 12. Cahn Z, Siegel M. Electronic cigarettes as a harm reduction strategy for tobacco control:
 a step forward or a repeat of past mistakes? . *Journal of Public Health Policy* 2011;32(1):16-31.
- 13. Ministry of Health. Smokefree Aotearoa 2025 Action Plan. Wellington, NZ: Ministry of
 Health, 2021.
- 14. Donny EC, Denlinger RL, Tidey JW, et al. Randomized Trial of Reduced-Nicotine
 Standards for Cigarettes. *N Engl J Med* 2015;373(14):1340-9. doi:
 10.1056/NEJMsa1502403
- 40 15. McLaren L, McIntyre L, S. K. Rose's population strategy of prevention need not increase 41 social inequalities in health. *International Journal of Epidemiology* 2010;39(2):372-42 77. doi: 10.1093/ije/dyp315
- 16. Charters C, Stavenhagen R, Translation E, et al. The United Nations Declaration on the
 Rights of Indigenous Peoples. 2009
- 17. Scottish Government. Raising Scotland's Tobacco-free Generation Our Tobacco-Control
 Action Plan. Edinburgh: Scottish Government, 2018.

- 18. Puljevic C, Morphett K, Hefler M, et al. Closing the gaps in tobacco endgame evidence: a scoping review. *Tob Control* 2022;31(2):365-75. doi: 10.1136/tobaccocontrol-2021-056579 [published Online First: 2022/03/05]
- 19. Blakely T, Cobiac LJ, Cleghorn CL, et al. Health, health inequality, and cost impacts of
 annual increases in tobacco tax: multistate life table modeling in New Zealand. *PLoS medicine* 2015;12(7):e1001856.
- 7 20. Pearson AL, Cleghorn CL, van der Deen FS, et al. Tobacco retail outlet restrictions:
 8 health and cost impacts from multistate life-table modelling in a national population.
 9 *Tob Control* 2016 doi: 10.1136/tobaccocontrol-2015-052846 [published Online First: 20160922]
- 21. van der Deen FS, Wilson N, Cleghorn CL, et al. Impact of five tobacco endgame strategies on future smoking prevalence, population health and health system costs: two modelling studies to inform the tobacco endgame. *Tobacco control* 2018;27(3):278-86.
- 22. Huang V, Head A, Hyseni L, et al. Identifying best modelling practices for tobacco
 control policy simulations: a systematic review and a novel quality assessment
 framework. *Tob Control* 2022 doi: 10.1136/tobaccocontrol-2021-056825 [published
 Online First: 2022/01/13]
- 23. Doan TTT, Tan KW, Dickens BSL, et al. Evaluating smoking control policies in the ecigarette era: a modelling study. *Tobacco control* 2020;29(5):522-30.

21

22

- 24. Blakely T, Moss R, Collins J, et al. Proportional multistate lifetable modelling of preventive interventions: concepts, code and worked examples. *International Journal of Epidemiology* 2020;49(5):1624-36. doi: 10.1093/ije/dyaa132
- 25. Ministry of Health. Health Loss in New Zealand 1990–2013: A report from the New
 Zealand Burden of Diseases, Injuries and Risk Factors Study. Wellington: Ministry of
 Health, 2016.
- 26. Murray C, Ezzati M, Lopez A, et al. Comparative quantification of health risks:
 Conceptual framework and methodological issues. *Popul Health Metr* 2003;1(1):1.
- 27. Mendez D, Warner KE. A magic bullet? The potential impact of e-cigarettes on the toll of cigarette smoking. *Nicotine and Tobacco Research* 2021;23(4):654-61.
- 28. Wilson N, Hoek J, Nghiem N, et al. Modelling the impacts of tobacco denicotinisation on achieving the Smokefree 2025 goal in Aotearoa New Zealand. *NZ Med J* 2022;135(1548)
- 29. Pearson AL, Cleghorn CL, van der Deen FS, et al. Tobacco retail outlet restrictions:
 health and cost impacts from multistate life-table modelling in a national population.
 Tob Control 2017;26:579–85. doi: 10.1136/tobaccocontrol-2015-052846
- 30. Blakely T, Cobiac LJ, Cleghorn CL, et al. Health, Health Inequality, and Cost Impacts of
 Annual Increases in Tobacco Tax: Multistate Life Table Modeling in New Zealand.
 PLoS Med 2015;12(7):e1001856. doi: 10.1371/journal.pmed.1001856
- 40 31. Nghiem N, Cleghorn CL, Leung W, et al. A national quitline service and its promotion in 41 the mass media: modelling the health gain, health equity and cost—utility. *Tobacco* 42 *Control* 2017;27(4):434-41. doi: 10.1136/tobaccocontrol-2017-053660
- 43 32. Anderson I, Robson B, Connolly M, et al. Indigenous and tribal peoples' health (The Lancet–Lowitja Institute Global Collaboration): a population study. *The Lancet* 2016;388(10040):131-57. doi: https://doi.org/10.1016/S0140-6736(16)00345-7
- 46 33. Blakely T, Barendregt JJ, Foster RH, et al. The association of active smoking with multiple cancers: national census-cancer registry cohorts with quantitative bias

1 analysis. *Cancer Causes Control* 2013;24(6):1243–55. doi: 10.1007/s10552-013-0204-2 [published Online First: 2013/04/13]

3

4

5

6

7

8

9

- 34. Hunt D, Blakely T, Woodward A, et al. The smoking-mortality association varies over time and by ethnicity in New Zealand. *Int J Epidemiol* 2005;34:1020-28.
- 35. Thun M, Apicella L, Henley S. Smoking vs other risk factors as the cause of smoking-attributable deaths. Confounding in the courtroom. *JAMA* 2000;284:706-12.
- 36. Hoogenveen R, van Baal P, Boshuizen H, et al. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation. *Cost Eff Resour Alloc* 2008;6:1-15. doi: doi: 10.1186/1478-7547-6-1
- 37. Petrovic-Van Der Deen FS, Blakely T, Kvizhinadze G, et al. Restricting tobacco sales to
 only pharmacies combined with cessation advice: A modelling study of the future
 smoking prevalence, health and cost impacts. *Tobacco Control* 2019;28(6):643-50.
 doi: 10.1136/tobaccocontrol-2018-054600 [published Online First: 2018/11/11]
- 38. Edwards R, Johnson E, Hoek J, et al. The Smokefree 2025 Action Plan: key findings
 from the ITC New Zealand (EASE) project. In: Expert PH, ed. Public Health Expert.
 Wellington: University of Otago, 2021.

Tables and Figures

Table 1: Baseline and business-as-usual parameters

Parameter	Data Source	Trend, Uncertainty, and Scenario Analyses					
Demography							
Population	Statistics New Zealand (SNZ) population estimates for 2018 by sex, age-group, and ethnicity.	Uncertainty: nil					
BAU – epidemiological parar	neters						
All-cause mortality rates (ACMR)	SNZ mortality rates by sex, age, and ethnicity for 2020	Trends in ACMR were estimated using GHDx data (IMME). The annual percentage change in the age-standardised all-cause mortality rates from 1990 to 2019 was -1.9% for sexes combined. Retaining the original BODE3 model assumption of a 0.5 percent point greater APC for Māori (due to long run trends of closing ethnic inequalities in mortality), we arrived at APC's for ACMR from 2020 to 2035 of: Māori = -2.0%; non-Māori =-1.5%. They were uniform by age. No trends applied beyond 2035.					
		Uncertainty: nil.					
All-cause morbidity rates	NZ Burden of Disease Study ²⁵	Data on years of life lived with disability (YLD) were obtained from the NZBDS for each sex and age group in 2016 and divided by the population in each sex by age by ethnic group to generate morbidity rates. No time trend was allowed.					
Disease specific incidence, prevalence, and case-fatality rates	NZ Burden of Disease Study ²⁵	For each tobacco-related disease, coherent sets (by sex, age, and ethnicity) of incider rates, prevalence, case-fatality rates (CFR), and remission rates (zero for non-cancer the complement of the CFR for cancers to give the expected 5-y relative survival) we estimated using DISMOD II.					
		Cancer incidence and CFR annual percentage change (APC) trends using Poisson regression historic trends of incidence and case-fatality rates of diseases. The APCs included as inputs to the PMSLT model out to year 2035 and held constant beyond (future prevalence changes dynamically with model). It was assumed that the APCs were constant by ethnicity.					
		Uncertainty: starting in 2020, rates all +/- 5% standard deviation (SD), correlations 1.0 between four sex by ethnic group categories for all diseases. APC all +/- 0.5% SD normal, correlations 1.0 between four sex by ethnic groups for all diseases.					
Disease specific morbidity	NZ Burden of Disease Study ²⁵	The sex and age specific disability rates were calculated as disease's YLD obtained divided by the prevalent cases.					
		The same disability rate was assumed by ethnicity (i.e., those with disease are assumed					

Parameter	Data Source	Trend, Uncertainty, and Scenario Analyses					
		to have same severity distribution across ethnicity).					
		Uncertainty: +/- 5% SD (beta distribution)					
Tobacco smoking and vaping							
Smoking (daily)	NZ Health Survey	Logistic regression of NZ Health Survey data for years 2011 to 2019 was undertaken to 'predict' the prevalence of daily smoking (at least one cigarette per day) for years 2020 to 2040. This 'prediction file' was then re-analysed from a sex by ethnicity by five-year age group perspective (i.e., 72 separate sex by age by ethnicity cohorts) to generate future BAU smoking prevalence – and a yearly (cohort aging) rate of decline – that was then used in the exposure model.					
Vaping (daily e-cigarette use)	NZ Health Survey	Same as above for smoking, but for 'vaping' at least daily.					
Association of smoking and va	ping with disease incidence rates						
Smoking-disease incidence rate ratios	Relative risks of disease incidence for the association of current (or ex-smoker) with never smoker were sourced from NZ linked censuscancer ³³ and census-mortality ³⁴ (censuses include smoking question) and CPS II data for respiratory diseases. ³⁵ Attenuation over time since quitting for ex-smokers was modelled using equations and coefficients from Hoogenveen et al. ³⁶	Standard errors of regression coefficients as described in Appendix C					

Table 2: Intervention input parameter table

Parameter	Description
Denicotinisation	
NS→ CS (age 20 only) NS→ DU (age 20 only)	10% (SD 5%) of BAU initiation at age 20 by five years after implementation (X= Beta (3.6, 32.4), median 9.3%, 95% UI 2.6% to 21.5%.). Implemented as X ^(t/5) scalar applied to the BAU initiation rates in years t (1 to 5) after introduction of the policy, then held at X% thereafter.
CS→ FSFV CS→ FSCV DU→ FSFV DU→ FSCV	Using an expert knowledge elicitation (see Appendix D), smoking prevalence (i.e. X=prevalence in states CS and DU) with mean 15.2% (SD 7.84%, X=Beta (3.19, 17.78), median 14.1%, 95% UI: 3.7% to 32.9%) of BAU smoking prevalence five years after low nicotine policy implementation, due to quitting or switching to vaping (i.e. disregarding initiation impacts that will additionally impact prevalence among 20-24 year olds in first five years of the model). Implementation was as $X^{(t/5)}$ scalar applied to BAU CS and DU prevalence where t is the 1 to 5 years after intervention. For the sixth and subsequent years, the transition probabilities were twice those in BAU (due to an ongoing higher NCR, given non-addictive levels of nicotine in tobacco).
NS→NSCV	No change.
Denicotinisation plus Mass media	
$NS \rightarrow CS$ (age 20 only)	As above for low nicotine.
NS→ DU (age 20 only)	As above for low nicotine.
NS→ NSCV (age 20 only)	No change.
CS→ FSFV CS→ FSCV DU→ FSFV DU→ FSCV	As above for low nicotine from year 1 to 5 + twice the absolute contribution of the routine media/Quitline campaign to background net cessation (i.e. $1.055\% \times 2 = 2.1\%$) ³¹ Subsequent years: transition to quitting or vaping were twice those in BAU
Retail outlet restriction to about 300 outlets (abo	out 5% of current outlets; assumed supply of e-cigarettes reduces commensurately) †
NS→ CS	As per the increase in cessation probabilities (CS→FSFV, etc, below), we reduced the initiation rate by X= Beta (23.4, 97.2), median 19.2%, 95% UI: 12.9% to 26.9%. Applies in 2023 onwards (as youth contemplating initiating in the future confront lesser retail availability as well).

Parameter	Description
NS→ DU	As above for NS→CS.
CS→ FSFV CS→ FSCV DU→ FSFV DU→ FSCV	As a low estimate of one-off quitting, we used that from studies modelling reducing retail outlets in terms of increased travel costs ³⁷ : a reduction in the prevalence of 15.6% for Māori, and 16.0% for non-Māori – or 15.8% overall.
De / Ide /	As a high estimate, we used that from the NZ ITC study where – in response to a question whether they would quit in response to a 95% reduction in retail outlets - 23.0% said they would quit (half quitting \rightarrow FSFV, half switching to FSCV). ³⁸
	Placing the mean at 19.4% (average of above 15.8% and 23%) and using 15.8% and 23% as one SD either side of the mean (SD = 3.6%), we parameterised the one-off increase in smoking net cessation as X=Beta (23.4, 97.2), median 19.2% (i.e., percentage point increase), 95% UI: 12.9% to 26.9%. Note this increase was on top of BAU transition probabilities, and halved over CS \rightarrow FSFV and CS \rightarrow FSFV, and halved over DU \rightarrow FSFV and DU \rightarrow FSCV. E.g. if the CS \rightarrow FSFV was 5%, the intervention CS \rightarrow FSFV transition probability was 5% + (1-5%)×0.5×X%. This effect was in the year of intervention only— in years after the retail outlet restriction, the transition probabilities out of CS and DU reverted to BAU.
NS→NSCV	Unchanged
Tobacco-free generation	
Smoking initiation rate (NS→ CS; occurs only at age 20)	For two reasons, a tobacco-free generation proposal will not immediately achieve zero uptake at age 20; 1) our model for parsimony assumes all uptake at age 20, but the minimum legal age of purchasing is 18 years; 2) social supply will allow some young people to keep initiating. We therefore assumed that initiation at age 20 in our model (essentially an average of all initiation by [say] age 25) will asymptote to a mean of X=10% (SD 5%) of BAU in 10 years (Beta (3.6, 32.4), median 9.3%, 95%UI: 2.6% to 21.5%), with the scalar of BAU initiation rate of $X^{\wedge(t'10)}$ for $t=1$ to 10 years after the tobacco-free generation policy is implemented, then X of BAU initiation thereafter.
NS→ DU	As above for NS→CS.
NS→ NSCV	Unchanged [†]

Parameter	Description
Combined: Denicotinisation + retail + tobacco	-free
NS→ CS (age 20 only)	Cumulative impact. If the % reduction in initiation in year t for denicotinisation, retail and tobacco-free was A%, B%, and C%, then the reduction in the combined intervention was $1 - (1-A)(1-B)(1-C)$.
NS→ DU (age 20 only)	As above for NS→CS.
CS→ FSFV CS→ FSCV DU→ FSFV	Cumulative impact. If the % increase in quitting or switching in year t for denicotinisation, media and retail was A% and B%, then the increase in the combined intervention was $1 - (1-A)(1-B)(1-C)$.
DU→ FSCV	
NS→ NSCV	Unchanged.

NS=never smoker; CS=current smoker (but not a dual user); DU=dual user; NSCV=never smoker, current vaper; FSFV=former smoker and/or former vaper; FSCV=former smoker current vaper.

†If the availability of alternative nicotine delivery systems (ENDS, e.g. e-cigarettes) does not reduce commensurately with these policy interventions, one would expect larger switched to ANDS which would reduce smoking prevalence further (but increase DU, FSCV and possibly NSCV state prevalence). We do not model this explicitly but consider it in the Discussion.

Table 3: Deaths averted† during 2020-30 and 2031-40, in Aotearoa New Zealand by strategy


Population	Year	Denicotinisation		Denicotinisation + media		Retail reduction		Smokefree generation		Combined interventions	
		Est	95%UI	Est	95%UI	Est	95%UI	Est	95%UI	Est	95%UI
	2020 to 2030	261	(183 to 339)	265	(188 to 341)	87	(58 to 123)	1	(0.39 to 0.77)	300	(233 to 368)
Female Māori (n= 428,948 in 2020)	2031 to 2040	1,780	(1,360 to 2,210)	1,800	(1,380 to 2,220)	441	(285 to 643)	14	(10 to 17)	1,890	(1,500 to 2,300
(n= 420,540 m 2020)	2020 to 2040	2,040	(1,540 to 2,550)	2,060	(1,570 to 2,560)	528	(344 to 764)	14	(10 to 18)	2,200	(1,740 to 2,650
	2020 to 2030	281	(196 to 367)	285	(201 to 370)	97	(64 to 138)	0	(0.31 to 0.62)	324	(252 to 401)
Female Non-Māori (n=2,132,141 in 2020)	2031 to 2040	1,940	(1,450 to 2,430)	1,960	(1,480 to 2,440)	496	(321 to 729)	9	(6.1 to 12)	2,070	(1620 to 2,530)
(n=2,102,1 11 m 2020)	2020 to 2040	2,220	(1,650 to 2,800)	2,240	(1,680 to 2,810)	594	(384 to 867)	9	(6.4 to 12)	2,390	(1,870 to 2,920
Male Māori	2020 to 2030	140	(97 to 183)	142	(101 to 184)	49	(32 to 69)	0	(0 to 0.01)	163	(127 to 200)
(n= 425,740 in 2020)	2031 to 2040	864	(651 to 1,070)	873	(661 to 1,080)	221	(145 to 321)	4	(2.6 to 4.8)	921	(726 to 1,120)
	2020 to 2040	1,000	(747 to 1,260)	1,010	(765 to 1,260)	270	(176 to 389)	4	(2.6 to 4.8)	1,080	(851 to 1,310)
	2020 to 2030	329	(229 to 431)	333	(236 to 433)	113	(75 to 160)	0	(0.12 to 0.28)	380	(298 to 468)
Male Non-Māori (n= 2,099,493 in 2020)	2031 to 2040	1,970	(1,500 to 2,440)	1,990	(1,520 to 2,450)	504	(330 to 734)	4	(2.6 to 5)	2,110	(1,670 to 2,540
(n= 2,000, 100 m 2020)	2020 to 2040	2,300	(1,730 to 2,860)	2,320	(1,760 to 2,870)	617	(405 to 892)	4	(2.7 to 5.3)	2,490	(1,980 to 3,000
	2020 to 2030										
All (n= 5,086,322 in 2020)	2020 to 2030 2031 to 2040	1,010	(707 to 1320)	1,020	(728 to 1,320)	346	(230 to 491)	1	(0.84 to 1.6)	1,170	(911 to 1,430)
	2020 to 2040	6,560 7,570	(4,990 to 8,160) (5,680 to 9,440)	6,620 7,640	(5,060 to 8,190) (5,780 to 9,490)	1,660 2,010	(1,080 to 2,420) (1,310 to 2,900)	30	(22 to 37) (23 to 39)	6,990 8,150	(5,520 to 8,470 (6,450 to 9,890

[†]Deaths averted over the period, i.e., total deaths over each ten-year period in BAU minus intervention.

Table 4: Health gain (in HALYs gained) for people alive in 2020 (base-year, N = 5,086,322) in Aotearoa New Zealand by the modelled policies, by timeline into the future (3% discount rate)


Donulation	Vacu	Denicotinisation		Denicotinisation + media		Re	etail reduction	Smokefree generation		Combined interventions	
Population	Year	Estimate	Estimate 95% UI		Estimate 95% UI		Estimate 95% UI		Estimate 95% UI		95% UI
Female Māori	2020 to 2030	955 (679 to 1,260)		971	(699 to 1,260)	335	(221 to 475)	23	(16 to 31)	1,130	(884 to 1,380)
	2031 to 2040	10,600	(7,990 to 13,100)	10,700	(8,160 to 13,100)	2,800	(1,830 to 3,990)	325	(242 to 406)	11,500	(9,370 to 13,700)
	2041 to 2131	151,000	(111,000 to 188,000)	151,000	(112,000 to 189,000)	24,800	(15,900 to 36,700)	29,900	(19,400 to 40,600)	157,000	(116,000 to 195,000)
	All	162,000	(120,000 to 202,000)	163,000	(121,000 to 203,000)	27,900	(18,000 to 41,100)	30,300	(19,700 to 41,000)	170,000	(127,000 to 210,000)
	2020 to 2030	1,450	(1,030 to 1,940)	1,470	(1,050 to 1,950)	525	(346 to 745)	23	(16 to 32)	1,710	(1,330 to 2,130)
Female Non-	2031 to 2040	14,700	(11,000 to 18,300)	14,800	(11,200 to 18,400)	3,990	(2,610 to 5,770)	334	(239 to 443)	16,000	(12,800 to 19,200)
Māori	2041 to 2131	142,000	(104,000 to 182,000)	143,000	(105,000 to 182,000)	28,200	(17,800 to 42,800)	15,300	(9,950 to 22,400)	149,000	(109,000 to 189,000)
	All	159,000	(116,000 to 201,000)	160,000	(117,000 to 202,000)	32,700	(20,800 to 49,200)	15,600	(10,300 to 22,900)	166,000	(124,000 to 209,000)
	2020 to 2030	596	(423 to 786)	606	(436 to 792)	214	(141 to 303)	17	(12 to 22)	707	(554 to 871)
	2031 to 2040	6,080	(4,570 to 7,520)	6,140	(4,670 to 7,560)	1,640	(1,070 to 2,350)	230	(171 to 291)	6,650	(5,360 to 7,940)
Male Māori	2041 to 2131	70,100	(49,400 to 90,600)	70,500	(49,600 to 91,000)	12,400	(7,990 to 18,800)	12,800	(8,220 to 18,100)	73,600	(52,100 to 94,200)
	All	76,700	(54,800 to 98,300)	77,200	(55,300 to 98,800)	14,300	(9,240 to 21,400)	13,000	(8,450 to 18,300)	80,800	(58,200 to 103,000)
	2020 to 2030	1,620	(1,140 to 2,150)	1,640	(1,170 to 2,160)	585	(384 to 830)	24	(16 to 33)	1,910	(1,500 to 2,360)
Male Non-Māori	2031 to 2040	15,900	(12,000 to 19,700)	16,000	(12,200 to 19,800)	4,300	(2,810 to 6,180)	345	(249 to 455)	17,300	(14,000 to 20,800)
viale Non-Maori	2041 to 2131	151,000	(112,000 to 193,000)	152,000	(112,000 to 193,000)	29,500	(18,900 to 44,400)	16,300	(10,800 to 23,800)	158,000	(119,000 to 199,000)
	All	168,000	(126,000 to 214,000)	169,000	(127,000 to 214,000)	34,400	(22,100 to 51,400)	16,700	(11,100 to 24,300)	177,000	(134,000 to 221,000)
	2020 to 2030	4,630	(3,260 to 6,140)	4,690	(3,360 to 6,170)	1,660	(1,090 to 2,360)	88	(60 to 118)	5,460	(4,280 to 6,740)
All population	2031 to 2040	47,400	(35,700 to 58,500)	47,800	(36,400 to 58,700)	12,700	(8,300 to 18,300)	1,230	(909 to 1,590)	51,500	(41,500 to 61,600)
	2041 to 2131	514,000	(378,000 to 650,000)	517,000	(380,000 to 653,000)	94,800	(60,900 to 143,000)	74,200	(49,000 to 104,000)	537,000	(396,000 to 673,000)
	All	566,000	(421,000 to 711,000)	569,000	(424,000 to 714,000)	109,000	(70,200 to 163,000)	75,500	(50,200 to 105,000)	594,000	(443,000 to 738,000)

Figure 1. Smoking prevalence (daily, 20+ year population) in Aotearoa New Zealand under business-as-usual and interventions




Note: Prevalences are not age-standardised and are calculated for the projected age-structure of each sex by ethnic group in future years.

Figure 2: Ratios of per capita HALY gains over the remainder of the 2020 Aotearoa-New Zealand population's lifespan, for Māori compared to non-Māori



Calculated using cohorts defined by age in 2020, age standardised using the 2020 Māori population.


Figure 3: Projected percentage changes in age-standardised all-cause mortality rate differences (≥ 45 years) between Māori and non-Māori, for endgame strategies [†] compared to BAU



SRD: Standardised rate difference. Rates are standardised to the $M\bar{a}ori\,population$

[†] We do not show the tobacco-free generation as there is no change in 45 plus year old mortality rates in this timeline.

Figure 4: Tornado plots of total HALYs (3% discount, lifetime) showing the ranking of smoking initiation and cessation parameters by how much uncertainty their 2.5th and 97.5th percentiles cause for the combined intervention policy package compared to BAU, for:



Percentile values for sensitivity analyses (taken from Table 2):

- Denicotinisation: annual smoking cessation rate. Cessation rates in first five years after policy implementation set to achieve 3.7% (2.5th percentile) or 32.9% (97.5th percentile) of BAU smoking prevalence [median = 14.1%].
- Retail reduction: annual smoking cessation rate. One off (in year of implementation) increase in cessation rate of 12.9 percentage points (2.5th percentile) or 26.9 percentage points (97.5th percentile) [median = 19.2 percentage points]. Note: when combined with denicotinisation (above), it acts on top of the 'new' (not BAU) denicotinisation cessation rate.
- Denicotinisation: annual smoking initiation rate. Initiation rate five years after policy implementation reduced to 2.6% (2.5th percentile) or 21.5% (97.5th percentile) of BAU initiation rates [median = 9.3%].
- Smokefree generation: annual smoking initiation rate. Initiation rate five years after policy implementation reduced to 2.6% (2.5th percentile) or 21.5% (97.5th percentile) of BAU initiation rates [median = 9.3%]. Note: when combined with denicotinisation (above), it acts on top of the 'new' (not BAU) denicotinisation cessation rate.
- Retail reduction: annual smoking initiation rate. Permanent decrease in initiation rate of 12.9% (2.5th percentile) or 26.9% (97.5th percentile) [median = 19.2%]. Note: when combined with denicotinisation and smokefree generation (above), it acts on top of the 'new' (not BAU) initiation rate.

Note the vertical black line of 610,073 HALYs is for the median value of all input parameters. It differs modestly from the 594,000 central estimate of HALYs in the main analyses, which is the median across all iterations of the Monte Carlo analyses.